Therapeutic | Amivantamab |
Target 1 | EGFR |
Heavy Chain 1 | QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS |
Light Chain 1 | AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK |
100% seqID Fv 1 Structure | None |
99% seqID Fv 1 Structure | None |
95-98% seqID Fv 1 Structure | None |
Target 2 | MET |
Heavy Chain 2 | QVQLVQSGAEVKKPGASVKVSCETSGYTFTSYGISWVRQAPGHGLEWMGWISAYNGYTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDLRGTNYFDYWGQGTLVTVSS |
Light Chain 2 | DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWFQHKPGKAPKLLIYAASSLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPITFGQGTRLEIK |
100% seqID Fv 2 Structure | 6wvz [Fvs: HL] |
99% seqID Fv 2 Structure | None |
95-98% seqID Fv 2 Structure | None |
100% seqID Structure [Fv 2] | 6wvz [Fvs: HL] |
There are no identical PDB matches to at least one Fv in this therapeutic. Click the links to build models with ABodyBuilder: [Fv 1] [Fv 2] |
Follow these links to our prediction tools:
Format | Bispecific mAb |
Isotype | G1;G1 |
Highest Clinical Trial (January '23) | Approved |
Estimated Status (January '23) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2019 |
INN Year Recommended | 2020 |
Companies Involved | Genmab, Janssen Research & Development |
Conditions Approved | Non-small cell lung cancer |
Conditions Active | Gastic cancer, Oesophageal cancer, Solid tumours |
Conditions Discontinued | na |
Notes |
SAbDab papers
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]
Thera-SAbDab paper
Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]